Palpable Lymphadenopathy In Clinical Practice

Palpable Lymphadenopathy In Clinical Practice: a multi-centre, prospective, case-control study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN99581977

Enrollment

200

Registered

2011-05-04

Start date

2011-04-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Palpable lymph node enlargement Cancer Lymphoma

Interventions

1. This is an observational study and all interventions are decided upon by the patients physician and are not influenced by the study design. 2. This study will collect data from clinical, ultrasound

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with palpable lymphadenopathy 2. Patients with radiologically proven, but still not palpable, peripheral lymphadenopathy 3. Patients with a sentinel node biopsy or regional dissections as part of their staging

Exclusion criteria

Exclusion criteria: 1. Patients unable or unwilling to give consent 2. Patients younger than 18

Design outcomes

Primary

Measure	Time frame
Determining the correlation between the parameters collected in our study through clinical and ultrasound examination with the: 1. Diagnosis of malignancy established by pathologic examination of the biopsied lymph node 2. Diagnosis of a benign disease established by pathologic examination of the biopsied lymph node 3. Diagnosis of a benign cause of lymphadenopathy established by spontaneous reversal of lymphadenopathy sustained over 3 months 4. The parameters collected are: 4.1. Clinical exam and history: age, sex 4.2. Node location and external size (2 dimensions) 4.3. Presence of splenomegaly 4.4. Pain on palpation 4.5. Lymph node texture (subjective) 4.6. Complete blood count (CBC) 4.7. Lactate dehydrogenase (LDH) 4.8. Erythrocyte sedimentation 4.9. Presence of night sweats 4.10. Pruritus 4.11. Unexplained loss of weight, or unexplained fevers 4.12. History of malignant diseases 4.13. Presence of any "supicious" lesion during a whole body physicial exam 5. Ultrasound: 5.1. Size, location and number of enlarged lymph nodes, echogenicity (hyper, hypo, hilar, diffuse, perinodal, localised) 5.2. Demarcation from surrounding tissue 5.3. Presence of necrosis 5.4. Vascularity (avascular, hillar, diffuse, peripheral, localised) 5.5. Calcifications 5.6. Presence of splenomegaly 5.7. Resistive and pulsatile index 6. Pathologic examination: 6.1. Size of lymph node 6.2. Microscopic morphology (normal-resembles lymph node, changed does not resemble a lymph node) 6.3. Presence of granulomas, necrosis or calcifications 6.4. Presence of metastasis and size 6.5. Final diagnosis	—

Measure

Time frame

Determining the correlation between the parameters collected in our study through clinical and ultrasound examination with the: 1. Diagnosis of malignancy established by pathologic examination of the biopsied lymph node 2. Diagnosis of a benign disease established by pathologic examination of the biopsied lymph node 3. Diagnosis of a benign cause of lymphadenopathy established by spontaneous reversal of lymphadenopathy sustained over 3 months 4. The parameters collected are: 4.1. Clinical exam and history: age, sex 4.2. Node location and external size (2 dimensions) 4.3. Presence of splenomegaly 4.4. Pain on palpation 4.5. Lymph node texture (subjective) 4.6. Complete blood count (CBC) 4.7. Lactate dehydrogenase (LDH) 4.8. Erythrocyte sedimentation 4.9. Presence of night sweats 4.10. Pruritus 4.11. Unexplained loss of weight, or unexplained fevers 4.12. History of malignant diseases 4.13. Presence of any "supicious" lesion during a whole body physicial exam 5. Ultrasound: 5.1. Size, location and number of enlarged lymph nodes, echogenicity (hyper, hypo, hilar, diffuse, perinodal, localised) 5.2. Demarcation from surrounding tissue 5.3. Presence of necrosis 5.4. Vascularity (avascular, hillar, diffuse, peripheral, localised) 5.5. Calcifications 5.6. Presence of splenomegaly 5.7. Resistive and pulsatile index 6. Pathologic examination: 6.1. Size of lymph node 6.2. Microscopic morphology (normal-resembles lymph node, changed does not resemble a lymph node) 6.3. Presence of granulomas, necrosis or calcifications 6.4. Presence of metastasis and size 6.5. Final diagnosis

—

Secondary

Measure	Time frame
No secondary outcome measures	—

Countries

Serbia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026